Sol-Gel Technologies Ltd. announced that TWYNEO®, a topical cream containing a fixed-dose combination of tretinoin, 0.1%, and benzoyl peroxide (BPO), 3% for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, is now available for purchase by consumers who obtain a prescription from their physician. TWYNEO Cream was approved by the U.S. Food and Drug Administration on July 27, 2021 and is being commercialized in the U.S. by Galderma. It is the first and only tretinoin and benzoyl peroxide (BPO) 2-in-1 combination ever approved by FDA and has been proven to rapidly treat even moderate to severe facial acne.

TWYNEO Cream is now available at all major pharmacy chains throughout the U.S. by prescription. TWYNEO Cream is a once-daily application that can be used any time of day and even for severe cases of acne, as indicated by a physician's prescription.